【佳學(xué)基因檢測】檢驗(yàn)科醫(yī)師晉升考試關(guān)于ADRA2C的知識

基因檢測的序列名稱：

ADRA2C

人體基因序列變化與疾病表征數(shù)據(jù)庫中的基因代碼：

152

人體基因序列數(shù)據(jù)庫中國際交流名稱全稱

adrenoceptor alpha 2C

中國數(shù)據(jù)庫中基因全稱：腎上腺素受體2C基因檢測報(bào)告英文版基因簡介

Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The mouse studies revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. The alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes the alpha2C subtype, which contains no introns in either its coding or untranslated sequences. [provided by RefSeq, Jul 2008]

基因突變所影響的基因信息

Alpha-2-腎上腺素受體是G蛋白偶聯(lián)受體超家族的成員。它們包括3個(gè)高度同源的亞型：alpha2A，alpha2B和alpha2C。這些受體在調(diào)節(jié)交感神經(jīng)和中樞神經(jīng)系統(tǒng)中腎上腺素能神經(jīng)元的神經(jīng)遞質(zhì)釋放中起關(guān)鍵作用。小鼠研究表明，正常的突觸前控制心臟中交感神經(jīng)和中樞去甲腎上腺素能神經(jīng)元的遞質(zhì)釋放需要alpha2A和alpha2C亞型。alpha2A亞型在高刺激頻率下抑制了遞質(zhì)的釋放，而alpha2C亞型在較低的神經(jīng)活動水平下調(diào)節(jié)了神經(jīng)傳遞。該基因編碼alpha2C亞型，該亞型在其編碼序列或非翻譯序列中均不??

國際國內(nèi)該堿基因序列的其他英語文字母簡稱：

ADRA2L2, ADRA2RL2, ADRARL2, ALPHA2CAR

基因解碼對該基因序列在細(xì)胞核中的染色體所給予的編號：

該基因序列位于人類第4號染色體上。

基因解碼對基因序列的正確定位

該基因序列在GRCh37版本中的起始位置坐標(biāo)為：3768296；結(jié)束位置坐標(biāo)為：3770253。該基因序列在GRCh38版本中的起始位置坐標(biāo)為：3766569；結(jié)束位置坐標(biāo)為：3768526。正確的基因信息定位是基因檢測和對檢測結(jié)果進(jìn)行正確解讀的關(guān)鍵。

佳學(xué)基因解碼對該基因的功能分類：國際版

G-protein coupled receptors/GPCRs excl olfactory receptors

基因解碼對該基因的功能分類：中文版

G 蛋白偶聯(lián)受體/GPCR 不包括嗅覺受體

結(jié)構(gòu)與功能基因解碼所揭示的該基因在細(xì)胞內(nèi)發(fā)揮作用的場所（國際版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

結(jié)構(gòu)與功能基因解碼所揭示的該基因發(fā)揮作用的細(xì)胞內(nèi)位置（中文版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

該基因序列變化后增加的疾病風(fēng)險(xiǎn)（國際版）：

Fibrosis; Cardiomegaly; Heart failure; Mood Disorders; Bipolar Disorder

如果該基因突變后，風(fēng)險(xiǎn)可能增加的疾病類型（中文版）：

纖維化；心臟肥大；心臟衰竭;情緒障礙；躁郁癥

GWAS基因檢測所建立的與該基因的疾病關(guān)聯(lián)（國際版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

GWAS基因檢測所解碼的該基因突變會增加風(fēng)險(xiǎn)的疾病種類（中文版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

以該基因做靶點(diǎn)的藥物（國際版）：

Ziprasidone (Protein homodimerization activity);Cabergoline (Protein homodimerization activity);Ropinirole (Protein homodimerization activity);Olanzapine (Protein homodimerization activity);Clozapine (Protein homodimerization activity);Norepinephrine (Protein homodimerization activity);Mirtazapine (Protein homodimerization activity);Loxapine (Protein homodimerization activity);Pramipexole (Protein homodimerization activity);Brimonidine (Protein homodimerization activity);Clonidine (Protein homodimerization activity);Lisuride (Protein homodimerization activity);Epinephrine (Protein homodimerization activity);Tizanidine (Protein homodimerization activity);Apomorphine (Protein homodimerization activity);Risperidone (Protein homodimerization activity);Tolazoline (Protein homodimerization activity);Fenoldopam (Protein homodimerization activity);Phenoxybenzamine (Protein homodimerization activity);Oxymetazoline (Protein homodimerization activity);Carvedilol (Protein homodimerization activity);Doxepin (Protein homodimerization activity);Pergolide (Protein homodimerization activity);Bromocriptine (Protein homodimerization activity);Quetiapine (Protein homodimerization activity);Aripiprazole (Protein homodimerization activity);Paliperidone (Protein homodimerization activity);Ephedra (Protein homodimerization activity);Yohimbine (Protein homodimerization activity);Methotrimeprazine (Protein homodimerization activity);Methamphetamine (Protein homodimerization activity);Dronedarone (Protein homodimerization activity);Iloperidone (Protein homodimerization activity);OPC-28326 (Protein homodimerization activity);Epicept NP-1 (Protein homodimerization activity);Mianserin (Protein homodimerization activity);Asenapine (Protein homodimerization activity);Droxidopa (Protein homodimerization activity);Xylometazoline (Protein homodimerization activity);Lurasidone (Protein homodimerization activity);Agmatine (Protein homodimerization activity);Brexpiprazole (Protein homodimerization activity)

針對該基因所產(chǎn)生的突變，可能有正確效果的藥物（中文版）：

齊拉西酮(蛋白質(zhì)同二聚化活性);卡麥角林(蛋白質(zhì)同二聚化活性);羅匹尼羅(蛋白質(zhì)同二聚化活性);奧氮平(蛋白質(zhì)同二聚化活性);氯氮平(蛋白質(zhì)同二聚化活性);去甲腎上腺素(蛋白質(zhì)同二聚化活性);米氮平(蛋白質(zhì)同二聚化活性);洛沙平(蛋白質(zhì)同二聚活性);普拉克索(蛋白質(zhì)同二聚活性);溴莫尼定(蛋白質(zhì)同二聚活性);可樂定(蛋白質(zhì)同二聚活性);麥角乙脲(蛋白質(zhì)同二聚活性);腎上腺素(蛋白質(zhì)同二聚活性);替扎尼定(蛋白質(zhì)同二聚活性);阿撲嗎啡(蛋白質(zhì)同二聚活性);利培酮(蛋白質(zhì)同二聚活性);托拉唑啉(蛋白質(zhì)同二聚活性);非諾多泮(蛋白質(zhì)同二聚活性);苯氧芐明(蛋白質(zhì)同二聚活性);羥甲唑啉(蛋白質(zhì)同二聚活性);卡維地洛(蛋白質(zhì)同二聚活性);多塞平(蛋白質(zhì)同二聚活性)同二聚活性);培高利特(蛋白質(zhì)同二聚活性);溴隱亭(蛋白質(zhì)同二聚活性);喹硫平(蛋白質(zhì)同二聚活性);阿立哌唑(蛋白質(zhì)同二聚活性);帕利哌酮(蛋白質(zhì)同二聚活性);麻黃(蛋白質(zhì)同二聚活性);育亨賓(蛋白質(zhì)同二聚活性)活性）；甲氧美拉嗪（蛋白質(zhì)同二聚化活性）；甲基苯丙胺（蛋白質(zhì)同二聚化活性）；決奈達(dá)?。ǖ鞍踪|(zhì)同二聚化活性）；伊潘立酮（蛋白質(zhì)同二聚化活性）；OPC-28326（蛋白質(zhì)同二聚化活性）；Epicept NP-1（蛋白質(zhì)同二聚化活性）；米安色林（蛋白質(zhì)同二聚化活性）；阿塞那平（蛋白質(zhì)同二聚化活性）；屈昔多巴（蛋白質(zhì)同二聚化活性）；賽洛唑啉（蛋白質(zhì)同二聚化活性）；魯拉西酮（蛋白質(zhì)同二聚化活性）；胍丁胺（蛋白質(zhì)同二聚化活性）；Brexpiprazole（蛋白質(zhì)同二聚化活性）

(責(zé)任編輯：佳學(xué)基因)